FDA Approves First Treatment for Non-CF Bronchiectasis|ASPEN Trial,COPD Inhalers,Platelet Guidelines

“In this episode of This Week in Pulmonary and Critical Care Medicine, Dr. Aladdin Sagar reviews the FDA approval of BRINSUPRI (brensocatib), the first therapy for non-cystic fibrosis bronchiectasis, and the pivotal ASPEN trial. We also cover a practical review on inhaler device selection in COPD and the 2025 AABB/ICTMG platelet transfusion guidelines. Stay current with the evidence that matters at the bedside. 📌 Articles discussed: • FDA approval press release – brensocatib 2025 https://investor.insmed.com › 2025-08-12-FDA-Appro... • ASPEN Trial – NEJM 2025 https://www.nejm.org/doi/full/10.1056... • COPD inhaler selection – CHEST 2025 https://journal.chestnet.org/article/... • Platelet transfusion guidelines – JAMA 2025 https://jamanetwork.com/journals/jama... For educational purposes only. Not a substitute for clinical judgment.”